Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and performance of the AltaValve System for treating moderate-to-severe or severe mitral regurgitation in patients who are not suitable for surgery or other catheter-based repair methods. This prospective, single-arm, multicenter clinical trial focuses on two patient groups those with and without moderate to severe mitral annular calcification MAC. Participants will receive the AltaValve System, a transcatheter mitral valve replacement device designed to improve heart valve function. The study includes two cohorts based on the presence of MAC. The trial assesses outcomes such as all-cause mortality, heart failure hospitalizations, valve function, and quality of life over a long period extending up to five years after implantation. During the study, participants undergo various evaluations including mortality and stroke monitoring, kidney function tests, bleeding assessments, and technical success of the device. Quality of life and exercise capacity are measured using questionnaires and walk tests at 6 months and 1 year. Follow-up includes monitoring for pacemaker use and any need for additional valve interventions. The primary outcome is a composite measure of death or heart failure hospitalization within 12 months, with continued assessments up to 5 years.
Actively Recruiting
Researchers are evaluating the use of one versus multiple arterial grafts in patients undergoing primary isolated non-emergency coronary artery bypass surgery CABG. This international, randomized trial aims to determine if multiple arterial grafts reduce a combined outcome of death, stroke, heart attack after discharge, or repeat revascularization, compared to a single arterial graft. The study also seeks to assess if multiple arterial grafts improve overall survival in these patients with coronary artery disease. Participants are randomly assigned to receive either a single arterial graft, which is the left internal thoracic artery plus venous grafts, or multiple arterial grafts including the left internal thoracic artery plus a second arterial graft such as the right internal thoracic artery or radial artery. Some patients in the multiple graft group may receive additional arterial grafts. This trial enrolls at least 4,300 patients across 25 international centers and uses a 11 randomization with stratification by center and graft type. During the study, participants will be monitored for outcomes including death, stroke, myocardial infarction, and repeat revascularization starting more than 72 hours after surgery. Additional assessments include 30-day mortality, postoperative complications, sternal wound healing, and hospital readmissions. Follow-up analyses will evaluate survival and cause-specific mortality over an average of 5 years. The study is expected to continue until 2030, with comprehensive safety and effectiveness monitoring throughout.